Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): An open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial

The Lancet Oncology

Volumn 15, Issue 9, 2014, Pages 975-985

  Fizazi, Karim ^a   Massard, Christophe ^a   Bono, Petri ^b   Jones, Robert ^c   Kataja, Vesa ^d   James, Nicholas ^e   Garcia, Jorge A ^f   Protheroe, Andrew ^g   Tammela, Teuvo L ^h   Elliott, Tony ⁱ   Mattila, Leena ^j   Aspegren, John ^j   Vuorela, Annamari ^j   Langmuir, Peter ^k   Mustonen, Mika ^j  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c VELINDRE CANCER CENTRE   (United Kingdom)

^d KUOPIO UNIVERSITY HOSPITAL   (Finland)

^e QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^f TAUSSIG CANCER INSTITUTE   (United States)

^g CHURCHILL HOSPITAL   (United Kingdom)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j ORION CORPORATION   (Finland)

^k Endo Pharmaceuticals   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; CYP17 INHIBITOR; CYTOCHROME P450 INHIBITOR; ODM 210; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FRACTURE; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; LACERATION; LONG TERM CARE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE INJURY; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NAUSEA; OPEN STUDY; PAIN; PARALYTIC ILEUS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRESYNCOPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; URINE RETENTION; VOMITING; WEIGHT REDUCTION; BLOOD; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; METASTASIS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TUMOR INVASION;

ADMINISTRATION, ORAL; AGED; ANDROGEN RECEPTOR ANTAGONISTS; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PATIENT SAFETY; PATIENT SELECTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84904983988     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70240-2     Document Type: Article

References (34)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V Prostate cancer: ESMO consensus conference Guidelines 2012. Ann Oncol 2013, 24:1141-1162. Panel Members, European Society for Medical OncologyEuropean Society for Medical Oncology.
3. Prostate Cancer. Version 3 NCCN Clinical Practice Guidelines in Oncology, (accessed April 4, 2014). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012, 13:983-992.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
6. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
7. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377:813-822.
8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012, 367:1187-1197.
9. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013, 369:213-223.
10. Scher HI, Sawyers CL Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
11. Massard C, Fizazi K Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 2011, 17:3876-3883.
12. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012, 368:138-148.
13. Egan A, Dong Y, Zhang H, Qi Y, Balk SP, Sartor O Castration-resistant prostate cancer: adaptive responses in the androgen axis. Cancer Treat Rev 2014, 40:426-433.
14. Fizazi K, Martinez LA, Sikes CR, et al. The association of p21((WAF-1/CIP1)) with progression to androgen-independent prostate cancer. Clin Cancer Res 2002, 8:775-781.
15. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013, 3:1020-1029.
16. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
17. Leibowitz-Amit R, Joshua AM Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions. Curr Oncol 2012, 19(suppl 3):S22-S31.
18. Fizazi K, Massard C, James ND, et al. ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: preclinical and phase I data. Proc Am Soc Clin Oncol 2013, 31(suppl 6). abstr 65.
19. Moilanen A, Riikonen R, Oksala R, et al. ODM-201-new generation antiandrogen with excellent antiandrogenic and antitumor activity in nonclinical models of CRPC. Eur J Cancer 2013, 49(suppl 2). abstr 685.
20. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008, 26:1148-1159.
21. Kumar RJ, Barqawi A, Crawford ED Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005, 7(suppl 5):S37-S43.
22. Siegel R, Naishadham D, Jemal A Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
23. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012, 72:1494-1503.
24. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446.
25. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. N Engl J Med 2014, published online June 1. 10.1056/NEJMoa1405095.
26. Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 2011, 71:480-488.
27. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010, 28:1496-1501.
28. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013, 24:1807-1812.
29. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013, 24:1802-1807.
30. Schrader AJ, Boegemann M, Ohlmann CH, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014, 65:30-36.
31. Badrising S, van der Noort V, van Oort IM, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014, 120:968-975.
32. Stein MN, Goodin S, Dipaola RS Abiraterone in prostate cancer: a new angle to an old problem. Clin Cancer Res 2012, 18:1848-1854.
33. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splicevariants. Clin Cancer Res 2011, 17:5913-5925.
34. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011, 71:6503-6513.